News
PRQR
2.705
+2.08%
0.055
Weekly Report: what happened at PRQR last week (1223-1227)?
Weekly Report · 12/30/2024 12:00
Weekly Report: what happened at PRQR last week (1216-1220)?
Weekly Report · 12/23/2024 12:08
Weekly Report: what happened at PRQR last week (1209-1213)?
Weekly Report · 12/16/2024 12:09
ProQR Therapeutics Price Target Maintained With a $8.00/Share by JMP Securities
Dow Jones · 12/12/2024 14:30
JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target
Benzinga · 12/12/2024 14:22
ProQR Therapeutics Expands Collaboration With RSRT With $8.1 Mln Funding For AX-2402
NASDAQ · 12/12/2024 13:11
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 12/12/2024 12:59
ProQR Therapeutics Price Target Maintained With a $4.00/Share by Chardan Capital
Dow Jones · 12/12/2024 12:59
ProQR’s Strategic Advancements and Financial Stability Drive ‘Buy’ Rating
TipRanks · 12/12/2024 12:55
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target
Benzinga · 12/12/2024 12:49
ProQR Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 12/12/2024 12:21
HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $10 Price Target
Benzinga · 12/12/2024 12:11
ProQR’s Strategic Positioning in RNA Editing Technology: A Buy Recommendation
TipRanks · 12/12/2024 11:35
ProQR’s Promising RNA-Editing Advancements and Strategic Collaborations Drive Buy Rating
TipRanks · 12/12/2024 05:45
ProQR Therapeutics Advances Axiomer RNA-Editing Platform with Strategic Partnerships
TipRanks · 12/11/2024 21:27
ProQR Secures $8.1 Million for Rett Syndrome RNA Therapy
TipRanks · 12/11/2024 12:27
ProQR Therapeutics announces $8.1M in new funding from RSRT
TipRanks · 12/11/2024 12:16
ProQR Receives $9.1M to Develop RNA Therapy for Rett Syndrome, Impacting 350,000 People
Benzinga · 12/11/2024 12:02
PROQR THERAPEUTICS ANNOUNCES $8.1 MILLION IN NEW FUNDING FROM RETT SYNDROME RESEARCH TRUST TO EXPAND RNA EDITING COLLABORATION
Reuters · 12/11/2024 12:00
ProQR Therapeutics Appoints Dr. Peter Beal as Chief ADAR Scientist to Advance RNA Editing Platform
Barchart · 12/10/2024 17:22
More
Webull provides a variety of real-time PRQR stock news. You can receive the latest news about Proqr Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About PRQR
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).